Objectives

After participating in this educational activity, attendees should be able to:

1) Describe the role of cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis

2) Assess the primary literature regarding efficacy and safety of elexacaftor/tezacaftor/ivacaftor that led to its recent FDA approval  for certain patients with cystic fibrosis

3) Define which patients are appropriate for treatment with elexacaftor/tezacaftor/ivacaftor 

4) Describe how elexacaftor/tezacaftor/ivacaftor impacts the future of cystic fibrosis treatment

Faculty

Jenna Lee, PharmD 
PGY1 Community-Based Pharmacy Resident
Pharmacist
Baystate Medical Center 

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.